Using monoclonal antibodies to treat COVID-19

According to the FDA, monoclonal antibodies are laboratory-produced molecules that act as substitute antibodies that can restore, enhance or mimic the immune system’s attack on cells. Monoclonal antibodies for COVID-19 mayblock the virus that causes COVID-19 from attaching to human cells, making it more difficult for the virus to reproduce and cause harm.

We continue to gather a collection of the best resources on our website for acute and long-term care medicine, especially as it relates to us in Washington. This includes the latest information about using monoclonal antibodies in the treatment of COVID. Here are links to the articles and guidance.

• Use of Monoclonal Antibody Products to Treat COVID-19 in Washington State — Washington State Department of Health, August 2, 2021
• Fact Sheet for Patients, Parents, and Caregivers; Emergency Use Authorization (EUA) of REGEN-COV (TM) — Regeneron Pharmaceuticals, Inc.
• Introducing Lisa: A New Pathway to Request Staff Support for Monoclonal Antibody Infusions in Assisted Living/Long-Term Care — Argentum
• Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 — New England Journal of Medicine